Discovery of SPH5030, a Selective, Potent, and Irreversible Tyrosine Kinase Inhibitor for HER2-Amplified and HER2-Mutant Cancer Treatment-Reference-Cited by-同舟云学术

Discovery of SPH5030, a Selective, Potent, and Irreversible Tyrosine Kinase Inhibitor for HER2-Amplified and HER2-Mutant Cancer Treatment

Published:2022-03-23 Issue:7 Volume:65 Page:5334-5354
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Li Di¹,Tu Yuanxiang²^ORCID,Jin Kaijun¹,Duan Lingjun¹,Hong Yuan¹,Xu Jia¹,Chen Na¹,Zhang Zhihui¹,Zuo Hongjian¹,Gong Wanchun¹,Zhang Jing¹,Wang Qian¹,Qian Hai²²^ORCID,Wang Xuenan³,Ke Ying¹,Xia Guangxin¹

Affiliation:

1. Central Research Institute, Shanghai Pharmaceuticals Holding Company Limited, Building 4, No. 898 Halei Road, Zhangjiang Hi-tech Park, Pudong New Area, Shanghai 201203, P. R. China

2. Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, P. R. China

3. Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, China Pharmaceutical University, Nanjing 210009, P. R. China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c00710

Reference41 articles.

1. NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer

2. EGF–ERBB signalling: towards the systems level

3. An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors